Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.
Daiichi aims to expand valemetostat into a new use, but Haihe Biopharma isn't far behind.
Dizal got a lucky break with golidocitinib, and now mid-stage data back the project’s activity in T-cell lymphoma.
But JNJ-75276617 still has much to prove.
Blueprint looks to a next-gen Ayvakit, while Cogent challenges with a molecule acquired from Daiichi Sankyo.
Merck sees clinical setbacks in Keylynk-008, Leap-001 and Keyvibe-002.